|
Salix Pharmaceuticals, Ltd. - Company Profile Snapshot
| Company Profile: |
Salix Pharmaceuticals, Ltd. |
| Ticker: |
SLXP |
| Exchanges: |
NAS |
| 2008 Sales: |
178,770,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED STATES |
| Employees: |
280 |
Business Description
Salix Pharmaceuticals, Ltd.. The Group's principal activities are developing and marketing prescription pharmaceutical products for the treatment of gastrointestinal disease that affect digestive tract. The Group uses third-party manufacturers to produce material for use in clinical trials and for commercial product. The Group's first marketed product, Colazal is approved by the Food and Administration for the treatment of mildly to moderately active ulcerative colitis and the first new oral therapy approved by the Food and Drug Administration (FDA) for this indication.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
